Results from the Phase IIIb FRONTIER5 trial demonstrated that Mim8 prophylaxis was well-tolerated when administered without a ...

Results from the Phase III BASIS trial show that once-weekly subcutaneous Hympavzi reduced annualized bleeding rates by 93% ...

The label update for Amyvid adds guidance for assessing amyloid plaque levels and may help inform diagnostic and treatment ...

Pedro Valencia, VP, asset strategy leadership, oncology, AbbVie, explains how the company partners with patient advocacy groups to identify unmet needs and prioritize patient-centered benefits in the ...

This is Prime Therapeutics’ latest research into GLP-1s and the long term impact of taking the medication. In October of last ...

Williams is entrepreneur-in-residence and is will help mentor and support women leading ventures supported by the program. Reckitt announced Reckitt Catalyst at the Cannes Lions International Festival ...